CSL shares: 1 number that investors shouldn't ignore

This one number has me rethinking a CSL investment.

Well, one of the biggest pieces of news on the ASX so far this week has been the blockbuster earnings of healthcare giant CSL Ltd (ASX: CSL). CSL delivered its full-year results for FY 2026 yesterday. And boy, did the markets grab them (and plenty of CSL shares) and run.

By the end of yesterday's session, the CSL share price had rocketed a massive 17.25% for its best day in 20 years.

As we covered yesterday, there were a lot of lukewarm numbers in this ASX 200 healthcare stock's latest report. The company reported total revenues of US$15.89 billion for the year ended 30 June 2026. That was down 1% year on year. Underlying net profits after tax dropped 2% to US$3.1 billion.

A number of one-off costs and impairments drove CSL to a statutory net loss after tax of US$2.6 billion.

However, as my Fool colleague Mark discussed yesterday, it seems that the unbridled optimism we have seen for CSL shares this week has stemmed from its optimistic guidance for FY 2027 and beyond.

CSL told investors to expect underlying net profits after tax growth of around 5% over FY27. This indicates a return to form is on the cards for a company that repeatedly dazzled investors for the decade leading up to 2020, before a series of events tanked the company's fortunes.

Hopefully, CSL can deliver this turnaround. But now, I want to focus on one metric that has caught my eye in CSL's latest numbers.

Woman flexes muscles after donating blood.

Image source: Getty Images

CSL shares surge despite a dividend hold

That metric is the final dividend that CSL will pay out in October. Yesterday, CSL revealed that this dividend will be worth US$1.60 per share. Coupled with April's interim dividend of US$1.30 per share, the company is set to dole out a total of US$2.92 in dividends per share in 2026.

That metric is significant because it marks only the second time that CSL will not be delivering a dividend hike to its shareholders. In fact, the last time that CSL didn't increase its year-on-year payouts was in 2022, largely thanks to the aftermath of the pandemic. You'd have to go back at least another decade to find any more instances of a dividend hold from this company.

This is a personal disappointment for me. I bought CSL shares many years ago, in part thanks to its strong history of dividend growth. As such, I was rather dismayed to see another hold on CSL's 2026 payout. A company's dividend growth is, in my view, one of the most vital indicators of a company's health. It is difficult to fudge and provides a sharp insight into the health of a company. Not to mention the fact that ASX shares that consistently grow their dividends over time tend to be market beaters.

Now, CSL has been upfront about its challenges for a while now. So this hold isn't really a surprise. But it is still something I didn't want to see. That's why I'll be watching the payouts that this company declares next year like a hawk.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »